# High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

> **NCT00003091** · PHASE2 · COMPLETED · sponsor: **Hoag Memorial Hospital Presbyterian** · enrollment: 40 (estimated)

## Conditions studied

- Kidney Cancer
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** recombinant interferon alfa

## Key facts

- **NCT ID:** NCT00003091
- **Lead sponsor:** Hoag Memorial Hospital Presbyterian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-01
- **Primary completion:** 2000-01
- **Final completion:** 2000-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003091, "High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*